- Home
- AARD vs CERS Comparison
AARD vs CERS Comparison
Compare AARD & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | CERS |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.9M | 276.0M |
| IPO Year | 2025 | 1997 |
Fundamental Metrics
Financial Performance| Metric | AARD | CERS |
|---|---|---|
| Price | $13.38 | $2.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $30.63 | $4.00 |
| AVG Volume (30 Days) | 178.7K | ★ 1.6M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $4.88 | $1.12 |
| 52 Week High | $19.58 | $2.24 |
Technical Indicators
Market Signals| Indicator | AARD | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 73.96 |
| Support Level | $9.18 | $1.71 |
| Resistance Level | $10.44 | $1.78 |
| Average True Range (ATR) | 0.91 | 0.12 |
| MACD | 0.46 | 0.05 |
| Stochastic Oscillator | 94.75 | 91.06 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.